Safety and Tolerability of MEDI3506 in Healthy Participants, in Participants With COPD and Healthy Japanese Participants
Status:
Completed
Trial end date:
2019-09-30
Target enrollment:
Participant gender:
Summary
This is a Phase 1, randomised, blinded, placebo controlled, study designed to evaluate the
safety, tolerability, pharmacokinetics, and immunogenicity response to single and multiple
doses of MEDI3506.